交易笔记
顶级投资人

顶级投资人

Warren BuffettCathie WoodLi LuRay DalioBill Ackman查看全部顶级投资人
历史归档
行业

AI & Compute

Semiconductors & AcceleratorsCloud & AI PlatformsData Center & NetworkingView all AI & Compute
研究
EN

FNA

Paragon 28, Inc.

Insider Trades

NameValueActionPriceCurrent Price
MPMVM Partners, LLC10 Percent Owner
$14M1M shares
SellMar 13, 2025
$13.04
--
MPMVM Partners, LLC10 Percent Owner
$2.1M164.7k shares
SellMar 6, 2025
$13.01
--
MPMVM Partners, LLC10 Percent Owner
$7.7M590.2k shares
SellMar 5, 2025
$13.02
--
MPMVM Partners, LLC10 Percent Owner
$8.1M619.7k shares
SellMar 4, 2025
$12.99
--
MPMVM Partners, LLC10 Percent Owner
$1.0M84.3k shares
SellJan 28, 2025
$11.94
--
MPMVM Partners, LLC10 Percent Owner
$315k27.1k shares
SellJan 27, 2025
$11.62
--
Trade FNA

About Paragon 28, Inc.

Paragon 28, Inc. is a medical device company specializing in the development, manufacturing, and global distribution of advanced surgical systems tailored for foot and ankle procedures. Its comprehensive product portfolio encompasses a wide array of solutions: Plating Systems: This includes the Gorilla plating series, offering specific solutions for Lisfranc injuries, Lapidus procedures, lateral column corrections, calcaneus slides, and naviculocuneiform (NC) fusions. Complementary products like Baby Gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates, as well as Silverback plating systems, are also available. Precision Guidance Technology: The company provides sophisticated guidance systems to enhance accuracy in various operations, such as fusion procedures for bunion deformities, first tarsometatarsal arthrodesis, metatarsal osteotomy for bunion correction, medial column beaming for Charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. Screw Systems: Paragon 28 offers robust screw systems, including the Monster, Mini Monster, and Joust beaming lines, which are critical for applications like bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, and fracture repair. Joint Replacement Solutions: Their offerings extend to total ankle replacement with the APEX 3D systems, alongside total talus spacers designed to replace the talus bone that links the leg and foot. Bunion/Hallux Valgus Correction Systems: Specifically for bunion management, the company provides nail systems such as the Phantom intramedullary nail systems, targeting severe hallux valgus cases. Orthobiologics: A substantial part of their product line comprises various orthobiologics, including bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix. They also feature PRESERVE bone graft systems for homologous applications. Ancillary Products: The company further supplies soft tissue fixation systems, titanium sprayed polyetheretherketone (PEEK) implants, nitinol staple systems, stabilization solutions, and specialized curved instruments. Paragon 28 distributes its products to hospitals and ambulatory surgery centers through an established network of both direct sales representatives and stocking distributors. Founded in 2010, the company maintains its corporate headquarters in Englewood, Colorado.

CEO
Albert DaCosta
IPO Date
Oct 15, 2021

Market Data

OpenThe first traded price for the current trading session.
$13.09
HighThe highest traded price in the current trading session.
$13.11
LowThe lowest traded price in the current trading session.
$13.07
VolumeTotal shares traded during the current trading session.
16.6M
Avg VolumeAverage number of shares traded per session, as reported by FMP.
2.6M
52W HighThe highest traded price over the past 52 weeks.
$13.13
52W LowThe lowest traded price over the past 52 weeks.
$4.65

Valuation

Market CapCompany equity value based on share price multiplied by shares outstanding.
$1.1B
Enterprise ValueMarket cap plus debt and other claims, less cash and equivalents.
$1.2B
Dividend YieldAnnualized dividend yield relative to the current share price.
0.00%

Financials

Free Cash FlowOperating cash flow minus capital expenditures from the latest annual cash flow statement.
$-44M
RevenueTotal sales from the latest annual income statement.
$256M
Net IncomeProfit after expenses and taxes from the latest annual income statement.
$-55M
CashCash and equivalents, or cash plus short-term investments, from the latest balance sheet.
$35M
DebtTotal debt from the latest balance sheet.
$111M

Events

EarningsMay 14

EPS est. -0.19 · actual -0.18

现代市场行业

AI & Compute

  • Semiconductors & Accelerators
  • Cloud & AI Platforms
  • Data Center & Networking

Software & Digital

  • Enterprise Software
  • Cybersecurity
  • DevTools & Observability
  • Consumer Internet & Marketplaces
  • Digital Advertising & Media

Healthcare

  • GLP-1 & Metabolic Health
  • Biotech & Oncology
  • Medical Devices & Diagnostics
  • Healthcare Services
  • Pharmaceuticals

Finance & Energy

  • Banks & Capital Markets
  • Asset Management & Exchanges
  • Insurance
  • Payments & Fintech
  • Digital Assets
  • Oil, Gas & Fuels

现代分类

  • AI & Compute Infrastructure
  • Software & Digital Platforms
  • Healthcare Innovation
  • Financial Infrastructure
  • Energy & Grid

细分行业

  • Semiconductors & Accelerators
  • Cloud & AI Platforms
  • Data Center & Networking
  • Enterprise Software
  • Cybersecurity
  • DevTools & Observability
  • Consumer Internet & Marketplaces
  • Digital Advertising & Media

动作类型

  • 投资人调仓
  • 高管交易
  • 国会交易
  • 股票动向

浏览

  • 历史归档
  • 行业
  • 分类
  • 顶级投资人
  • 关注列表
© 2026 交易笔记
历史归档行业分类顶级投资人关注列表